Nordhealth ASOSL:NORDH -2.40%75 Piotroski F-Score is 4 as of Jul. 03, 2026, which is 20% below its 10-year median of 5.00. GuruFocus rates OSL:NORDH with a GF Score™ of 75/100 and a GF Value™ of kr38.89 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 651 Healthcare Providers & Services companies, Nordhealth AS ranks worse than 67.59% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Nordhealth AS has an F-score of 4 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Nordhealth AS's Piotroski F-Score or its related term are showing as below:
OSL:NORDH'
s Piotroski F-Score Range Over the Past 10 Years
Min: 4 Med: 5 Max: 7
Current: 4
During the past 6 years, the highest Piotroski F-Score of Nordhealth AS was 7. The lowest was 4. And the median was 5.
Nordhealth AS (OSL:NORDH) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Nordhealth AS Piotroski F-Score Related Terms
Nordhealth AS Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Nordhealth AS's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSL:NORDH vs VEEV, BTSG, TEM: Piotroski F-Score Comparison
For the Health Information Services subindustry, Nordhealth AS's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nordhealth AS Piotroski F-Score vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Nordhealth AS's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Nordhealth AS's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Nordhealth AS's current Net Income (TTM) was -175.3.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Nordhealth AS's return on assets of this year was -0.17917209. Nordhealth AS's return on assets of last year was -0.08747025.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Nordhealth AS's current ratio of this year was 1.65472112. Nordhealth AS's current ratio of last year was 2.3700348.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Nordhealth AS's number of shares in issue this year was 78.814. Nordhealth AS's number of shares in issue last year was 79.066.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Nordhealth AS's gross margin of this year was 0.79971727. Nordhealth AS's gross margin of last year was 0.84658903.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Nordhealth AS's asset turnover of this year was 0.61227904. Nordhealth AS's asset turnover of last year was 0.52351093.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
0
+
1
+
1
+
0
+
1
+
0
+
1
=
4
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Nordhealth AS has an F-score of 4 indicating the company's financial situation is typical for a stable company.
Nordhealth AS (OSL:NORDH) has a Piotroski F-Score of 4 as of Jul. 03, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Nordhealth AS and its competitors. This is 20% below median its historical median of 5.00. Over the past decade, Nordhealth AS's Piotroski F-Score has ranged from 4.00 to 7.00. According to the industry distribution chart, Nordhealth AS ranks #440 out of 651 companies in the Healthcare Providers & Services industry, placing it in the top 67.6%.
Is Nordhealth AS's Piotroski F-Score too high?
Nordhealth AS's current Piotroski F-Score of 4 is 20% below median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 7.00. The Healthcare Providers & Services industry median Piotroski F-Score is 5.00. Nordhealth AS's value of 4 is 20% below this industry median. Based on the distribution chart, Nordhealth AS ranks #440 out of 651 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Nordhealth AS has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nordhealth AS's Piotroski F-Score compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Nordhealth AS ranks #440 out of 651 companies for Piotroski F-Score. This places Nordhealth AS in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Nordhealth AS's value of 4 is 20% below this benchmark. Historically, Nordhealth AS's own Piotroski F-Score has ranged from 4.00 to 7.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Nordhealth AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Healthcare Providers & Services company?
The median Piotroski F-Score among Healthcare Providers & Services companies is 5.00, based on 651 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nordhealth AS's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Nordhealth AS and its competitors. For the Healthcare Providers & Services industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nordhealth AS's current Piotroski F-Score is 4, which is 20% below median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nordhealth AS stock overvalued right now?
Based on GuruFocus' analysis, Nordhealth AS (OSL:NORDH) is currently considered Significantly Undervalued. The stock's GF Value™ is kr38.89, compared to a current price of kr24.40 — trading 37.3% below its estimated fair value. The current Piotroski F-Score is 4, which is 20% below median its 10-year median of 5.00 and 20% below the Healthcare Providers & Services industry median of 5.00. Nordhealth AS's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Nordhealth AS (OSL:NORDH), the current Piotroski F-Score is 4 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nordhealth AS (OSL:NORDH) Overvalued in 2026?
Based on GuruFocus' analysis, Nordhealth AS stock appears to be undervalued.
The current stock price of kr24.40 is trading 37.3% below its estimated GF Value™ of kr38.89.
GuruFocus considers Nordhealth AS to be Significantly Undervalued.
Key valuation signals for OSL:NORDH:
Piotroski F-Score: 4 (20% below median its 10-year median of 5.00)
GF Value™: kr38.89 vs. price of kr24.40 (37.3% below fair value)
Industry Position: 20% below the Healthcare Providers & Services median (#440 of 651)
No single metric tells the full story. See the OSL:NORDH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nordhealth AS is a cloud-based healthcare Software-as-a-Service business. Its flagship Practice Management Software (PMS), Provet for veterinary practices and Therapy Unified Platform for therapy practices, assist healthcare professionals to streamline operations and improve patient care. The majority of its revenue is generated through software subscriptions. The Group also offers additional services related to the implementation of the SaaS systems, including consultancy services, education, and data conversion. Its operating segments are: Veterinary, which generates the majority of revenue, Therapy, and Other. Geographically, Nordhealth derives maximum revenue from Norway, and the rest from Finland, the United Kingdom, Sweden, Denmark, the DACH region, and other countries.
75GF Score
Get the complete analysis for OSL:NORDH
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:NORDH has been successfully added to your 
